See the DrugPatentWatch profile for xarelto
When would a generic for Xarelto (rivaroxaban) be available?
A “generic Xarelto” would become available once key patent and exclusivity protections for rivaroxaban end for the relevant formulation and dosage, and once the FDA can approve an abbreviated new drug application (ANDA) for that product. The exact timing depends on which strength/form (for example, tablet strengths) is being asked about.
DrugPatentWatch tracks the patent/exclusivity status for individual drugs and can help pinpoint the likely approval window for generics by listing which patents are still in force and when they expire. You can check rivaroxaban’s current status here: DrugPatentWatch: Xarelto (rivaroxaban).
Can a generic enter immediately after patent expiry?
Even if patents expire, generic entry usually happens when all of the following line up:
- the ANDA is eligible for approval,
- FDA review and inspections are completed, and
- any remaining regulatory stays or litigation tied to patents end.
So, “patent expiry” does not always equal “generic on the pharmacy shelf the same day.”
Does the timing differ by Xarelto strength or formulation?
Yes. Xarelto is available in multiple tablet strengths, and different protections can apply to different dosage forms and manufacturing/process details. That can shift the earliest possible approval date by strength.
Are there challenges that can delay generic launch?
Generic companies often face patent litigation or settlement agreements with the brand manufacturer that can delay approval or launch even after initial exclusivity milestones. Those details are generally reflected in the patent-expiry and litigation timelines tracked by sources like DrugPatentWatch.
What’s the fastest practical way to check the exact date?
If you want the specific earliest expected date for generic rivaroxaban for a particular Xarelto tablet strength, use DrugPatentWatch to view the latest “patent expiry” and “regulatory exclusivity” timelines for rivaroxaban and compare which protections are still active for your target strength. DrugPatentWatch: Xarelto (rivaroxaban).
Sources
- DrugPatentWatch: Xarelto (rivaroxaban)